- Aptevo Therapeutics (NASDAQ:APVO +4.6%) collects in full $0.75M placed into an escrow account for working capital adjustments.
- This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY, to Medexus Pharmaceuticals.
- The transaction, completed in February 2020, included an upfront payment to Aptevo of $30M; additionally Aptevo is eligible to receive potential milestone payments of up to $11M from Medexus.
- Also, for up to 15 years, Aptevo will receive deferred payments on future US and Canadian net sales of IXINITY at a low to mid-single digit percentage of net sales.